Medications that block the activity of the pro-inflammatory molecule interleukin-17A (IL-17A) can ease symptoms of ankylosing spondylitis (AS), but…
Articles by Marisa Wexler MS
AbbVie‘s Rinvoq (upadacitinib) has been approved in the European Union to treat active ankylosing spondylitis (AS)…
The U.S. Food and Drug Administration (FDA) has approved a generic version of Pfizer‘s Celebrex (celecoxib), an oral medication…
Among people with non-radiographic axial spondyloarthritis (nr-axSpA) — a type of arthritis that mainly affects the joints of…
Treatment with Cimzia (certolizumab pegol) can ease eye inflammation in people with ankylosing spondylitis (AS), and reduce symptoms in those…
Treatment with Xeljanz (tofacitinib) was found to significantly ease symptoms of ankylosing spondylitis (AS) in a Phase 3 clinical trial.
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops…
Treatment with Humira (adalimumab) increases work productivity, reduces sleep problems, and eases disease activity in people with ankylosing…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
People with ankylosing spondylitis (AS) often endure considerable psychological distress — including depression, anxiety, and stress — that is…